CN102617884A - 一种人血清白蛋白医用生物材料的制作方法 - Google Patents
一种人血清白蛋白医用生物材料的制作方法 Download PDFInfo
- Publication number
- CN102617884A CN102617884A CN2012100731830A CN201210073183A CN102617884A CN 102617884 A CN102617884 A CN 102617884A CN 2012100731830 A CN2012100731830 A CN 2012100731830A CN 201210073183 A CN201210073183 A CN 201210073183A CN 102617884 A CN102617884 A CN 102617884A
- Authority
- CN
- China
- Prior art keywords
- serum albumin
- human serum
- gel
- sponge
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 71
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 71
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 239000012620 biological material Substances 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000011187 glycerol Nutrition 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims abstract description 18
- 108090000190 Thrombin Proteins 0.000 claims abstract description 16
- 238000007710 freezing Methods 0.000 claims abstract description 16
- 230000008014 freezing Effects 0.000 claims abstract description 16
- 229960004072 thrombin Drugs 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000004132 cross linking Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000013016 damping Methods 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 7
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 108010023321 Factor VII Proteins 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000012460 protein solution Substances 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- 108010076282 Factor IX Proteins 0.000 claims description 2
- 101000782195 Homo sapiens von Willebrand factor Proteins 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229940034998 human von willebrand factor Drugs 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 abstract description 46
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 230000032823 cell division Effects 0.000 abstract description 2
- 239000012567 medical material Substances 0.000 abstract description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 2
- 238000004140 cleaning Methods 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 17
- 239000006260 foam Substances 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 239000008367 deionised water Substances 0.000 description 15
- 229910021641 deionized water Inorganic materials 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 208000032843 Hemorrhage Diseases 0.000 description 13
- 230000023597 hemostasis Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000004872 arterial blood pressure Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000001105 femoral artery Anatomy 0.000 description 4
- 230000000025 haemostatic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical class O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
Images
Landscapes
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210073183.0A CN102617884B (zh) | 2012-03-19 | 2012-03-19 | 一种人血清白蛋白医用生物材料的制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210073183.0A CN102617884B (zh) | 2012-03-19 | 2012-03-19 | 一种人血清白蛋白医用生物材料的制作方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102617884A true CN102617884A (zh) | 2012-08-01 |
CN102617884B CN102617884B (zh) | 2014-03-05 |
Family
ID=46558121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210073183.0A Active CN102617884B (zh) | 2012-03-19 | 2012-03-19 | 一种人血清白蛋白医用生物材料的制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102617884B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105879126A (zh) * | 2016-03-24 | 2016-08-24 | 杭州亚慧生物科技有限公司 | 一种超润滑血清白蛋白泪点塞及其制备方法 |
CN109528627A (zh) * | 2018-12-03 | 2019-03-29 | 深圳大学 | 一种Ru-BSA水凝胶及其制备方法与应用 |
CN110721343A (zh) * | 2019-11-01 | 2020-01-24 | 河南省直第三人民医院 | 一种能修复凹陷性或萎缩性瘢痕的gfg凝胶及制备方法及应用 |
CN113042016A (zh) * | 2021-04-25 | 2021-06-29 | 上海捷门生物技术有限公司 | 用于纯化抗血清的固相亲和吸附剂以及获得纯化的抗体的方法 |
CN113713180A (zh) * | 2021-08-31 | 2021-11-30 | 尚诚怡美(成都)生物科技有限公司 | 一种交联人源白蛋白真皮填充剂及其制备方法 |
CN114377189A (zh) * | 2021-12-10 | 2022-04-22 | 广东省科学院健康医学研究所 | 一种止血复合水凝胶及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035843A1 (en) * | 1990-09-12 | 2003-02-20 | Lifecell Corporation, A Delaware Corporation | Method for processing and preserving collagen-based tissues for transplantation |
CN101612113A (zh) * | 2009-06-23 | 2009-12-30 | 武汉海特生物制药股份有限公司 | 一种神经生长因子海绵剂及其制备方法 |
CN101745327A (zh) * | 2009-12-29 | 2010-06-23 | 浙江大学 | 一种在聚合物微孔膜表面固定生物分子的方法 |
-
2012
- 2012-03-19 CN CN201210073183.0A patent/CN102617884B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035843A1 (en) * | 1990-09-12 | 2003-02-20 | Lifecell Corporation, A Delaware Corporation | Method for processing and preserving collagen-based tissues for transplantation |
CN101612113A (zh) * | 2009-06-23 | 2009-12-30 | 武汉海特生物制药股份有限公司 | 一种神经生长因子海绵剂及其制备方法 |
CN101745327A (zh) * | 2009-12-29 | 2010-06-23 | 浙江大学 | 一种在聚合物微孔膜表面固定生物分子的方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105879126A (zh) * | 2016-03-24 | 2016-08-24 | 杭州亚慧生物科技有限公司 | 一种超润滑血清白蛋白泪点塞及其制备方法 |
CN109528627A (zh) * | 2018-12-03 | 2019-03-29 | 深圳大学 | 一种Ru-BSA水凝胶及其制备方法与应用 |
CN109528627B (zh) * | 2018-12-03 | 2022-04-15 | 深圳大学 | 一种Ru-BSA水凝胶及其制备方法与应用 |
CN110721343A (zh) * | 2019-11-01 | 2020-01-24 | 河南省直第三人民医院 | 一种能修复凹陷性或萎缩性瘢痕的gfg凝胶及制备方法及应用 |
CN113042016A (zh) * | 2021-04-25 | 2021-06-29 | 上海捷门生物技术有限公司 | 用于纯化抗血清的固相亲和吸附剂以及获得纯化的抗体的方法 |
CN113713180A (zh) * | 2021-08-31 | 2021-11-30 | 尚诚怡美(成都)生物科技有限公司 | 一种交联人源白蛋白真皮填充剂及其制备方法 |
CN114377189A (zh) * | 2021-12-10 | 2022-04-22 | 广东省科学院健康医学研究所 | 一种止血复合水凝胶及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102617884B (zh) | 2014-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10076590B2 (en) | Modified starch material of biocompatible hemostasis | |
JP5883895B2 (ja) | 生物相容性の止血、癒着防止、癒合促進、外科密封可能な変性澱粉材料 | |
CN101455857B (zh) | 生物相容性变性淀粉海绵 | |
JP6363186B2 (ja) | 止血パッドのアセンブリキット及び方法 | |
US8475812B2 (en) | Gelatin sponge comprising an active ingredient, its preparation and use | |
AU2009259828B2 (en) | Compressible/expandable medical graft products, and methods for applying hemostasis | |
US7709017B2 (en) | Implantable preparations | |
CN102617884B (zh) | 一种人血清白蛋白医用生物材料的制作方法 | |
JP2002513645A (ja) | 止血化合物および生体吸収性ポリマーを含む組成物 | |
Nepal et al. | Advances in haemostatic sponges: Characteristics and the underlying mechanisms for rapid haemostasis | |
AU2016210617B2 (en) | Hemostatic device | |
JP2011509932A5 (zh) | ||
CN101121041A (zh) | 变性淀粉可吸收性止血材料及其制备方法 | |
CN102724968A (zh) | 干粉血纤蛋白密封剂 | |
CN104857552B (zh) | 一种止血贴及其制备方法 | |
Mecwan et al. | Recent advances in biopolymer-based hemostatic materials | |
US11357883B1 (en) | Method for preparing absorbable haemostatic composition for body and haemostatic composition prepared thereby | |
Pavliuk et al. | Characteristics of structured medical hemostatic sponges as a medical devices for stop bleeding and for close the wound | |
CN112300418B (zh) | 一种可粘附高效止血微球及其制备方法 | |
JP2006528672A5 (zh) | ||
US11311643B2 (en) | Fibrin and/or dialdehyde starch hydrolysate materials, and preparation and use thereof | |
Hu et al. | Gelatin sealing sheet for arterial hemostasis and anti-adhesion in vascular surgery: a dog model study | |
Altıntop et al. | A novel hemostatic scaffold material and the importance of scaffold formation on ending hemorrhage: An experimental rat study. | |
CN108553681A (zh) | 一种止血医用敷料及其制备方法 | |
Grimaldi et al. | Biotechnological Approaches to Hemostasis and Molecular Mechanisms of Wound Healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIAXING QIANGTE BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHU MINGHUA Effective date: 20121108 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310008 HANGZHOU, ZHEJIANG PROVINCE TO: 314031 JIAXING, ZHEJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20121108 Address after: 1409, room 1888, old car building, No. 314031 West Zhongshan Road, Zhejiang, Jiaxing Applicant after: JIAXING QIANGTE BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 310008 Datong village, Shangcheng District, Zhejiang, Hangzhou, 6-1-302 Applicant before: Zhu Minghua |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HANGZHOU YAHUI BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: JIAXING QIANGTE BIOTECHNOLOGY CO., LTD. Effective date: 20140728 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 314031 JIAXING, ZHEJIANG PROVINCE TO: 310051 HANGZHOU, ZHEJIANG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140728 Address after: Hangzhou City, Zhejiang province Binjiang District 310051 shore road 688 Building 2, building 328, room 333 E Patentee after: HANGZHOU YAHUI BIOTECHNOLOGY CO., LTD. Address before: 1409, room 1888, old car building, No. 314031 West Zhongshan Road, Zhejiang, Jiaxing Patentee before: JIAXING QIANGTE BIOLOGICAL TECHNOLOGY CO., LTD. |